ArticleNeuro-oncology2022

Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.

Alain CharestPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.